Background: This study investigated the optimal timing of concurrent chemoradiotherapy (CCRT) following surgery for patients with newly diagnosed glioblastoma (GBM). The focus was on understanding whether the interval between surgery and CCRT impacts survival outcomes.
Methods: Data from the Korean National Health Insurance Research Database ( https://opendata.hira.or.kr/ ) were collected to retrospectively review 3,586 patients diagnosed with GBM in South Korea between 2008 and 2021. Patients were divided into early CCRT (≤ 21 days between surgery and CCRT) and late CCRT (> 21 days between surgery and CCRT) groups and further categorised based on the type of surgery (biopsy alone or surgical resection). The study estimated overall survival (OS) and conducted univariable and multivariable Cox regression analyses.
Results: The median overall survival (OS) for the entire cohort was 19.98 months (95% Confidence Interval [CI]: 19.12-20.86 months). In univariable analysis, the late CCRT group demonstrated a longer median OS compared to the early CCRT group (20.47 vs. 17.94 months, P = 0.0002, log-rank test). However, this difference was not significant in multivariable analysis (Hazard Ratio [HR] = 0.98, 95% CI: 0.782-1.091, P = 0.6663). Subgroup analysis revealed that late CCRT was associated with prolonged OS in patients who underwent surgical resection (adjusted HR = 0.85, 95% CI: 0.752-0.955, P = 0.0065), whereas in the biopsy-alone group, late CCRT was associated with shorter OS (adjusted HR = 1.80, 95% CI: 1.378-2.346, P < 0.0001).
Conclusions: Patients who initiated CCRT more than 21 days post-resection demonstrated improved overall survival (OS) compared to those who began CCRT earlier. In contrast, among patients who underwent biopsy alone, initiating CCRT within 21 days was associated with better outcomes. These findings suggest that the optimal timing for CCRT initiation in GBM may depend on the extent of residual tumour.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590524 | PMC |
| http://dx.doi.org/10.1186/s12885-024-13223-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimal timing of chemoradiation after resection or biopsy of glioblastomas: a nationwide population-based study.
BMC Cancer
November 2024
Department of Neurosurgery, Brain Tumor Center, Ajou University School of Medicine, Ajou University Hospital, 164 Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Republic of Korea.
Background: This study investigated the optimal timing of concurrent chemoradiotherapy (CCRT) following surgery for patients with newly diagnosed glioblastoma (GBM). The focus was on understanding whether the interval between surgery and CCRT impacts survival outcomes.
Methods: Data from the Korean National Health Insurance Research Database ( https://opendata.
Case report: Metastatic gastric squamous cell carcinoma with long duration of complete response via three-staged radical concurrent chemoradiotherapy.
Heliyon
November 2024
Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
Introduction: Primary Gastric Squamous Cell Carcinoma (GSCC), especially in late-stage, is a very rare pathological type with poor prognosis. We report a long duration of Complete Response (CR) of GSCC case with multiple metastases by an elaborate three-staged radical Concurrent Chemoradiotherapy (CCRT).
Case Presentation: A 36-year-old male suffered from weakness and melena, and then was diagnosed as primary GSCC with cT3N3M1, Stage IV.
Background: This study evaluates functional larynx preservation in patients with hypopharyngeal cancer (HPC) and laryngeal cancer (LC) who achieved complete remission following radiotherapy (RT) or concurrent chemoradiation (CCRT).
Methods: HPC and LC patients treated with RT/CCRT from 1999 to 2017 were retrospectively analyzed. Severe late dysphagia and tracheostomy cases were assessed to determine laryngeal function.
Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
Radiother Oncol
November 2024
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China. Electronic address:
Background: The effectiveness and safety of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in elderly patients with locoregionally advanced nasopharyngeal carcinomas (LANPCs) remain subjects of debate. This study evaluated the efficacy of IC+CCRT compared to CCRT alone in elderly LANPC patients.
Materials And Methods: This retrospective, single-center study analyzed 335 elderly patients diagnosed with stage III or IVa NPC who received CCRT with or without IC between 2010 and 2016.
Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation.
Adv Radiat Oncol
April 2024
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Purpose: Conventional chemoradiation (CCRT) is inadequately effective for the treatment of unresectable or inoperable biliary tract cancers (UIBC). Ablative radiation therapy (AR), typically defined as a biologically effective dose (BED) ≥80.5 Gy, has shown some promise in terms of local control and survival in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!